NAFDAC alerts Nigerians over circulation of counterfeit breast cancer drug Phesgo
The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a warning about the circulation of counterfeit versions of Phesgo 600mg, a drug used in the treatment of breast cancer.
The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a warning about the circulation of counterfeit versions of Phesgo 600mg, a drug used in the treatment of breast cancer.
This was disclosed in a public notice issued by the agency.
According to the alert, the counterfeit products were reported by the Lagos University Teaching Hospital (LUTH-NSIA), where patients presented suspected fake Phesgo injections for administration.
NAFDAC said the Marketing Authorization Holder, Roche, received complaints involving suspected counterfeit batches B2346B16 and C3809C5.
Roche’s investigation identified the following discrepancies when compared with genuine products.
NAFDAC also revealed that batch number B2346B16 has been linked to confirmed counterfeit cases in multiple countries, including Nigeria, Turkey, and the Philippines.
Phesgo 600mg (Pertuzumab/Trastuzumab) is a critical drug used in the treatment of breast cancer. It works by targeting and stopping the growth of cancer cells.
Consumers and healthcare professionals are urged to report suspected counterfeit medicines to NAFDAC through its official channels.
NAFDAC has continued to intensify its alerts and enforcement actions against unsafe and falsified medical products in Nigeria.
In a recent notice, the agency warned about the recall of MR.7 SUPER 700000 male enhancement capsules after the product was found to contain undeclared pharmaceutical ingredients, posing serious health risks to consumers.
Another is on the circulation of falsified Dostinex 0.5mg tablets in Nigeria. The legitimate product is registered but not yet imported, while the fake batches, GG3470, LG8659, and GG2440, have no NAFDAC registration and may be unsafe
